6hk1: Difference between revisions

← Older edit

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

OCA

@@ Line 7: / Line 7: @@
 <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6hk1 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6hk1 OCA], [http://pdbe.org/6hk1 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6hk1 RCSB], [http://www.ebi.ac.uk/pdbsum/6hk1 PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6hk1 ProSAT]</span></td></tr>
 </table>
+<div style="background-color:#fffaf0;">
+== Publication Abstract from PubMed ==
+Obtaining crystals and solving the phase problem remain major hurdles encountered by bio-crystallographers in their race to obtain new high-quality structures. Both issues can be overcome by the crystallophore, Tb-Xo4, a lanthanide-based molecular complex with unique nucleating and phasing properties. This article presents examples of new crystallization conditions induced by the presence of Tb-Xo4. These new crystalline forms bypass crystal defects often encountered by crystallographers, such as low-resolution diffracting samples or crystals with twinning. Thanks to Tb-Xo4's high phasing power, the structure determination process is greatly facilitated and can be extended to serial crystallography approaches.
+Protein crystal structure determination with the crystallophore, a nucleating and phasing agent.,Engilberge S, Wagner T, Santoni G, Breyton C, Shima S, Franzetti B, Riobe F, Maury O, Girard E J Appl Crystallogr. 2019 Jun 28;52(Pt 4):722-731. doi: 10.1107/S1600576719006381., eCollection 2019 Aug 1. PMID:31396026<ref>PMID:31396026</ref>
+From MEDLINE&reg;/PubMed&reg;, a database of the U.S. National Library of Medicine.<br>
+</div>
+<div class="pdbe-citations 6hk1" style="background-color:#fffaf0;"></div>
+== References ==
+<references/>
 __TOC__
 </StructureSection>